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Background: Complementary and alternative medicine includes a diverse group of medical and
healthcare systems, practices and products not considered part of conventional medicine. Although
there is information on unconventional practices in oncological diseases, specific data regarding
the use of complementary and alternative medicine by hematology patients is scarce.
Objective: The aim of this study is to document the prevalence of this modality of unconventional
therapy in patients with malignant and benign hematological diseases, particularly children with
acute lymphoblastic leukemia.
Methods: An observational study of adult patients and guardians of children with malignant or
benign hematological diseases was carried out by applying a structured questionnaire detailing the
use and results of the most prevalent complementary and alternative medicine practices.
Results: One hundred and twenty patients were included; 104 had malignant and 16 had benign
hematological diseases. The use of complementary and alternative medicine was greater in benign
diseases but the difference was not statistically significant (64.7% versus 41.7%; p-value = 0.08).
Patients and guardians with high school or college educations used these alternative practices more
than patients with less schooling (60.7% versus 54.7%; p-value = 0.032). The use of folk remedies
was most prevalent followed by herbal preparations and spiritual healing. Sixty-four percent of
patients that used these unconventional practices reported improvement in their symptoms and
increased capacity to perform daily activities.
Conclusion: No significant difference was documented between patients with malignant or benign
hematological diseases using these alternative practices. The majority of complementary and
alternative medicine users reported improvement of the disease or chemotherapy-related symptoms.
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Introduction
Complementary and Alternative Medicine (CAM) consists of the use of any medical
system, practice or products not considered a medical therapy by conventional western
medicine as practiced by healthcare professionals holding a medical degree.(1) The
underlying rationale for many of these therapies is based on a form of magical thinking
derived from imagined anatomical analogies;(2) this takes the form of anatomical
correspondences where the body part – the eye in iridology or the ear in auricular
acupuncture – is treated as a microcosm representing the whole body, but can also
involve correspondences with the treatment itself such as some herbal medicines or other
natural phenomena, as in acupuncture.(2) The most common CAM used by patients include
homeopathy, herbal medicine, acupuncture, folk remedies, nutritional therapies, shiatsu,
iridology, shaman rituals, and yoga.(3)
The reported incidence of CAM use by oncology patients in industrialized
countries ranges from 25% to 84%.(1) Studies from Iran, Israel, Jordan, and Turkey
reported a high prevalence of CAM use, especially herbal medicine, along with spiritual
practices in both pediatric and adult patients diagnosed with breast, hemato-oncological,
gynecological and other cancers.(3) The high cost of conventional therapy, restricted
access to medical care, and dissatisfaction either of the bedside manners of the doctor
or the outcome of treatment, are some of the most common reasons that patients give
for using CAM.(4) The use of diverse CAM treatments by hemato-oncologic patients
satisfies an important psychological urge. When a patient is diagnosed with a life-
threatening disease, a feeling of hopelessness and loss of control over his or her life
develops.(5) Therefore, CAM therapy can be seen by patients as a way of regaining
control in decision-making related to the treatment of their disease, giving them the
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feeling that they can influence their current and future health
status.(6)
CAM use by oncology patients, as well as the isolated
use of various CAM methods, has been previously
reported.(7,8) Most of the patients that use CAM do so without
the physician being aware or without the physician's consent
due to fear of being criticized and the perception that their
doctor will disapprove or minimize CAM as a co-adjuvant
therapy.(9) There is a lack of information regarding the use of
CAM by patients with hematological diseases.
Objective
The aim of this study was to document the prevalence
of this modality of unconventional therapy in patients with
malignant and benign hematological diseases currently on
conventional treatment. Additionally, their opinions on the
severity and chronicity of their hematological disease were
documented as was their perception of the improvement of
symptoms using CAM.
Methods
An observational, cross-sectional and descriptive study
was conducted from February 1st 2009 to July 31st 2009 by
applying an ad hoc questionnaire during interviews of all
adult patients and parents or guardians of children diagnosed
with malignant or benign hematological diseases that
consented to participate. At the time of the study, patients
enrolled were receiving conventional treatment according to
their disease in the Hematology Department of the Hospital
Universitário "Dr. José Eleuterio González" of the Facultad
de Medicina, Universidad Autónoma de Nuevo León -
UANL. Incomplete questionnaires were excluded. Interviews
were conducted by a specially trained healthcare worker.
Questions regarding the use of different CAM
modalities (acupuncture, folk remedies, shaman spiritual
healing, homeopathic medicine, iridology and others) were
answered on a 'yes' or 'no' basis. If the answer was positive,
the duration of use of CAM in months was recorded and
whether the patient (or guardians) perceived any improvement
in symptoms. Asthenia, adynamia, anorexia, depression and
limitation in daily activities are the most commonly reported
symptoms. Additionally, perception regarding disease
severity (mild, moderate, serious and very serious) and the
duration of the disease (chronic or not) were documented.
Information regarding years of schooling was gathered for
adult patients as this group was responsible for taking
decisions regarding CAM. Finally we asked if the patient
was currently using any type of CAM and if the disease
limited the patient's daily activities and/or led to days off
work or school. Family income was documented by a social
worker. Univariate analysis estimating frequencies, central
tendencies according to the distribution of variables and
bivariate analysis using the χ2 test were carried out.
Results
One hundred and thirty-one patients were interviewed,
11 (8%) patients were excluded as their questionnaires were
incomplete and thus 120 (92%) participated in this study; 104
with malignant hematological diseases and 16 with benign
diseases. Diagnoses by age group are shown in Table 1 and
documented CAM is presented in Table 2. The distribution
of responses to the questionnaire is shown in Table 3.
Fifty-six percent of the patients had been sick for more
than one year at the time of the interview. Forty-five percent
of all patients reported that they had tried CAM (Table 2)
including homeopathy, herbal remedies, acupuncture, folk
remedies, shaman rituals and iridology. Folk remedies were
the most commonly used (38%) whereas the most efficient
were herbal remedies with 71% of the patients that used this
CAM reporting an overall improvement in their health.
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In the malignant group, men more frequently used
some type of CAM compared to women (54.8% vs. 45.2%;
p-value = 0.031); the median age was 29 years old (range:
1-89 years). Thirty percent of adult patients in this group
had only attended elementary school, 19.7% high school and
22.7% held a college degree; 4.6% had not finished elementary
school. The average family monthly income was US$500.00.
Adult patients were divided in two groups according to their
schooling: less than high school (basic education) and high
school and college education. Patients with basic education
used less CAM than those with more years of schooling
(54.7% vs. 60.7%; p-value = 0.032).
The prevalence of CAM use by patients with benign
hematological diseases was higher than patients with
malignant pathologies but this difference was not statistically
significant (41.7% vs. 64.7%; p-value = 0.08). Of these, 68.8%
of patients were female and 31.2% were male; half had had
the disease for more than three years. Most of the adult
patients of this group had only studied elementary school. A
total of 81.3% of all patients thought their disease was curable
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and did not see it as a chronic pathology. More than 88% of
those with malignant hematological diseases believed that
their disease was curable and 58.7% of them or their guardians
did not think that the illness was chronic.
Thirty percent of patients with malignant hematological
diseases used more than one CAM method, 95% of them
believed that they would be cured (p-value = 0.001) and 66%
did not think of their disease as chronic (p-value < 0.05).
These results were similar to patients that did not use CAM
(86% and 53%, respectively; p-value = 0.27).
With respect to the perception of illness severity, 37.5%
of both malignant and benign groups thought that their
diseases were serious and 25% of patients in each group
perceived them as very serious. Sixty-nine percent of the
patients with malignant hematological diseases who perceived
their disease as serious or very serious used CAM, compared
to 31% in this same group who did not perceive their disease
in that way (p-value = 0.04).
About half of the patients (52%) with malignant
hematological diseases reported limitations to perform daily
activities and 55% missed work or school sometimes. On
the other hand, 65% of those with benign hematological
diseases did not report having such limitations and 71%
did not miss work or school (p-value > 0.05). Patients who
perceived their disease as serious or very serious frequently
missed work or school (p-value = 0.003 and p-value = 0.048,
respectively) and those who perceived their disease as very
serious reported more limitations to perform daily activities
(p-value = 0.007). In the group with benign hematological
diseases, there was no difference between the patient's
perception of the severity of disease and missing work or
school (p-value = 0.39) or on limitations to perform daily
activities (p-value = 0.62). Most of the patients that used
some kind of CAM missed work or school more frequently
than those who did not use alternative therapies (60% vs.
23%; p-value < 0.05); this, however, was not related to the
severity of the disease.
The vast majority of patients with malignant
hematological diseases who used some modality of CAM
tried folk remedies (91%) recommended by their family or
friends, followed by herbal remedies (33%). Sixty-four percent
of all CAM users reported improvements in their disease or
chemotherapy-related symptoms (Table 2). The most
commonly reported symptoms are asthenia, adynamia,
anorexia, abdominal pain, nausea, dizziness, fatigue, headache
and depression. Sixty percent of the patients with malignant
hematological diseases did not use any kind of CAM.
As 51% of the study group (31 children and 20 adults)
had acute lymphoblastic leukemia (ALL), this was the most
frequent malignant diagnosis with non-Hodgkin's lymphoma
being the second commonest malignant disease (5 children
and 14 adults – Table 1). About half of the children with ALL
(16 patients) received some form of CAM treatment compared
to 12 adults; there was no statistical difference between these
groups (p-value = 0.41).
For the benign group, the most common diagnosis
among adults was idiopathic thrombocytopenic purpura
(57.1%) followed by autoimmune hemolytic anemia (21.4%),
whereas in children autoimmune hemolytic anemia and aplastic
anemia were the only two benign diseases observed.
Discussion
The use of CAM reflects a need to seek different
manners to alleviate the suffering caused by severe diseases
as well as some of the chemotherapy-related symptoms such
as nausea, vomiting, pain, anxiety and fatigue. This need
motivates the patient's quest for therapies congruent with
his/her beliefs.(10) Several studies have stated that cancer
patients use CAM therapies more frequently,(11) especially
those who had suffered their disease for a longer period of
time and those for whom conventional medical treatment has
failed.(5,12)
Patients with malignant hematological diseases also
have complications related to the chemotherapeutic regimen;
it would be reasonable to believe that some patients may
improve with different modalities of CAM.(7-9,13) In a study
addressing this issue in patients with different chronic
diseases, 86% of those with oncology diagnoses used herbal
remedies and perceived this modality as effective.(14) The
perception of the effectiveness of CAM by patients suffering
from hematological diseases has not been previously
documented. The use of CAM by the patients in this study,
both with malignant or benign hematological diseases,
appears to be related to the patients' or their guardians'
perception of the severity or chronicity of the disease,
probably reflecting a uniform cultural phenomenon in this
population.
We found that 41.7% of the study group used CAM;
this was more common for those individuals in the benign
disease group (62.5%) than those with malignant diseases
(42.3%; p-value = 0.032). These results are similar to
outcomes reported for Japanese, Canadian and Turkish
hemato-oncologic patients (44.6%, 49.0% and 47.0%,
respectively),(15-17) but less than outcomes in the USA, which
are reported as high as 83.3%.(1)
Previous studies in industrialized countries show that
being female, of high socioeconomic status and of high
education level are factors associated with the use of
CAM.(6,18,19)
Our results differ as the prevalence of CAM use in
malignant diseases was higher in men than in women. There
was a direct relationship between the number of years
schooling and the use of CAM; patients who studied longer,
more frequently resorted to CAM modalities; thus the data
of the current study agrees with other published studies.(1)
The association between socioeconomic status and the use
of CAM is controversial.(18-20) The vast majority of patients
attending our hospital belong to the low socioeconomic
group and most of them did not use CAM; those who did,
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did not suspend or substitute the prescribed conventional
chemotherapy.
A prevalence of 39.4% was reported in a recent large
cohort study that assessed CAM use in pediatric cancer
survivors, with 46% using more than one therapy.(21)
To the best of our knowledge, the use of CAM in a
group of patients with hematological diseases has not been
reported previously. Parental perception of the severity and
chronicity of children's disease probably explains the
similarities in the patterns of the use of CAM by adult patients.
We found a statistically significant difference in relation
to the use of CAM and perception of severity between the
malignant and benign groups. Although the majority of our
patients using CAM reported improvement in the disease or
in their treatment-related symptoms, this was not reflected
on days missed from work or school, which was similar for
both groups.
The expectations of the oncology patient that turns to
CAM are that this modality will help to improve symptoms,
enhance quality of life and well-being, provide a feeling of
control regarding the progression of the disease, and even
offer a cure.(11) This agrees with our results, as practically all
of our patients believed that they would be cured and more
than half with malignant or benign diseases did not think
that theirs was a chronic condition.
CAM modalities have the potential of improving the
quality of life directly or with a placebo effect. There have
been reports that show that, apart from receiving
psychological help,(8) patients taking some form of CAM tend
to be more optimistic and do not contemplate death as a
possibility.(1)
Nevertheless the use of CAM therapies may result in
harmful drug interactions and convey a risk to patients and
clinical trials as this will affect the results if the patient is
enrolled in one. Possible dangerous side effects of some
herbal remedies may affect the liver function which is already
threatened by chemotherapeutic agents; they can also cause
severe myelosuppression, hemostatic defects and impairment
of renal function.(12) There have been reports that the
pharmacokinetics of agents such as imatinib are affected and
the plasma levels of irinotecan are decreased with the use of
some natural health products.(22) Physicians must take time
to ask patients about the use of CAM and have sufficient
knowledge on these therapies to explain about possible
interactions with the patients' conventional therapy to assure
their wellbeing.
Our results contrast with other studies regarding the
use of CAM in two important aspects: most CAM users were
men and folk remedies were the most common type of CAM
chosen by patients diagnosed with hematological diseases.
However the results of this study agree to the fact that the
higher the education level, the greater the use of CAM.
The present study was carried out at a regional
reference hematology center, on a single ethnic population,
probably depicting more accurately the regional cultural
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behavior on CAM use; in contrast to other studies dealing
with CAM utilization, we focused only on patients with
hematological diseases and the study was carried out while
patients were receiving treatment. It is important to recognize
that patients with hematological diseases recur to CAM as
a way to improve their quality of life and to feel directly
involved in the decision-making regarding their disease and
future. Also, some CAM modalities can adversely affect
pharmacokinetics of chemotherapeutic agents, potentially
affecting treatment outcome. In consequence, physicians
should acknowledge that CAM use by hematological
patients is frequent and offers some benefits, in order to
advise and help them to receive the highest standard of
care available.
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